GEN Exclusives

More »

GEN News Highlights

More »
May 23, 2007

Pfizer Identifies Crystal Structure of Plk1

  • Researchers determined the structure of the Polo-like Kinase 1 (Plk1), a protein known to play a role in the progression of the cell cycle. Increased levels of Plk1 have also been associated with many cancers and are a negative prognostic indicator.

    Scientists from Pfizer global R&D used Fluidigm’s Topaz screening chips to investigate multiple mutant forms of Plk1. Novel crystallization conditions for the T210V mutant Plk1 kinase domain were identified and optimized in the chips. The results enabled the growth of crystals in vapor diffusion trials, which were used in structure determination. Complexes of Plk1 with the nonhydrolyzable ATP analogue adenylylimidodiphosphate or the pyrrolo-pyrazole inhibitor PHA-680626 were solved to 2.4 and 2.1 angstroms resolution, respectively.

    The research article was published in the May 22 issue of Biochemistry.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »